恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

未开盘 08-19 16:08:48

54.950

+0.700

+1.29%

最高55.550	最低54.100	成交量411.37万
今开54.250	昨收54.250	日振幅2.67%
总市值3,647亿	流通市值141.77亿	总股本66.37亿
成交额2.26亿	换手率1.59%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":54.95,"timestamp":1787126928004,"preClose":54.25,"halted":0,"volume":4113732,"delay":0,"changeRate":0.012903225806451665,"floatShares":258000000,"shares":6637000000,"eps":1.3745539942916287,"marketStatus":"未开盘","change":0.7,"latestTime":"08-19 16:08:48","open":54.25,"high":55.55,"low":54.1,"amount":225899960,"amplitude":0.026728,"askPrice":54.95,"askSize":1800,"bidPrice":54.85,"bidSize":2800,"shortable":3,"etf":0,"ttmEps":1.4219854261048206,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787189400000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":54.25,"dividendRate":0.004233,"openAndCloseTimeList":[[1787103000000,1787112000000],[1787115600000,1787126400000]],"volumeRatio":0.7542975759598487,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":52.66,"timestamp":1787122800000,"preClose":52.37,"halted":0,"volume":63799100,"delay":0,"premium":"-10.42"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"1142006575","title":"恒瑞医药（01276）宣布董事会秘书变更 刘笑含辞任田飞接任","url":"https://stock-news.laohu8.com/highlight/detail?id=1142006575","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142006575?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:21","pubTimestamp":1787149261,"startTime":"0","endTime":"0","summary":"2026年8月19日，恒瑞医药发布公告称，董事会秘书兼联席公司秘书刘笑含因个人原因提出辞职，辞职报告自送达董事会之日起生效。刘笑含原任期至2029年4月15日，其离任后不再在公司及控股子公司担任任何职务，亦不存在未履行完毕的公开承诺。公司确认其离任不会对正常运营造成影响，另一名联席公司秘书梁颖娴将继续履行公司秘书职责。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183935914","title":"恒瑞医药完成10.04亿元股份回购 1,659.10万股将用于员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1183935914","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183935914?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:20","pubTimestamp":1787149257,"startTime":"0","endTime":"0","summary":"2026年8月19日，江苏恒瑞医药股份有限公司公告称，其于2025年8月20日至2026年8月19日期间实施的A股股份回购已完成。本次回购共计购回16,591,040股，占公司总股本的0.25%。公司表示，已回购的1,659.10万股将全部用于实施A股员工持股计划，并承诺在回购完成后36个月内完成授予或转让；逾期未使用的股份将依法注销。回购完成后，公司总股本保持6,637,199,874股不变，其中回购专用证券账户股份余额为11,431,250股，占总股本的0.17%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660299334","title":"恒瑞医药(01276)：田飞获聘任为董事会秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2660299334","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660299334?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:20","pubTimestamp":1787149210,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，经公司董事长提名，并经公司董事会提名委员会审查通过，公司于2026年8月19日召开的第十届董事会第四次会议审议通过了《关于变更公司董事会秘书的议案》，同意聘任田飞先生为董事会秘书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","LU2488822045.USD","BK0183","BK0060","BK1191","LU1820825898.SGD","LU1997244956.HKD","LU2097828714.EUR","LU2580892789.USD","LU2148510915.USD","LU1655091616.SGD","LU1781817850.SGD","LU0405327494.USD","LU1146622755.USD","01276","LU1997245094.SGD","LU2495084118.USD","LU2289578879.USD","BK0239","LU2097828805.USD","LU2580892862.HKD","LU0405327148.USD","LU1580142542.USD","BK0012","BK0028","BK0196","LU1255011170.USD","600276","LU0359201612.USD","BK0188","LU1064131003.USD","LU0359201885.HKD","LU2097828631.EUR","LU1328615791.USD","LU2097828474.EUR","LU2543165471.USD","LU1023057109.AUD","LU1064130708.USD","LU1997245177.USD","LU1969619763.USD","LU2097828557.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660429685","title":"恒瑞医药(01276.HK)拟回购10亿-20亿元的A股股份用于 A 股员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2660429685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660429685?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:18","pubTimestamp":1787149098,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01276","03188","LU0359201885.HKD","LU0359201612.USD","83130","BK1147","BK1191","02846","83188","LU0359202008.SGD","82846","LU2543165471.USD","02827","07233","03130","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153343548","title":"恒瑞医药(01276)职工代表大会通过2026年A股员工持股计划草案","url":"https://stock-news.laohu8.com/highlight/detail?id=1153343548","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153343548?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:17","pubTimestamp":1787149025,"startTime":"0","endTime":"0","summary":"2026年8月19日，恒瑞医药股份有限公司公告称，公司第六届职工代表大会第五次会议已于2026年8月18日以现场结合通讯方式召开，并审议通过《关于<江苏恒瑞医药股份有限公司2026年A股员工持股计划（草案）>及其摘要的议案》。\\n\\n公司强调，在员工持股计划实施前已充分征求员工意见，公告中确认不存在损害公司及全体股东利益或强制员工参与的情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112295035","title":"恒瑞医药公布最高20亿元A股回购方案 期限不超12个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1112295035","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112295035?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:16","pubTimestamp":1787148980,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司8月19日发布公告称，公司董事会当日审议通过以集中竞价交易方式回购A股股份的方案，计划使用自有资金不低于10亿元、且不超过20亿元回购公司A股。恒瑞医药同时提示风险：若股票价格持续高于回购价格上限、资金未能及时到位、公司经营状况发生重大变化，或员工持股计划未能实施等，均可能导致回购方案变更或终止。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1172045194","title":"恒瑞医药（01276）公布2026年A股员工持股计划关键条款","url":"https://stock-news.laohu8.com/highlight/detail?id=1172045194","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172045194?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:15","pubTimestamp":1787148940,"startTime":"0","endTime":"0","summary":"2026年8月19日，恒瑞医药在上海证券交易所网站披露《2026年A股员工持股计划管理办法》，并同步刊发港交所海外监管公告，明确本次员工持股计划的核心安排如下：。单一持有人对应股份数量不超过公司总股本的1%，全部有效员工持股计划累计持股规模不超过公司总股本的10%。恒瑞医药表示，本计划旨在建立公司、股东与员工的利益共享机制，提升员工凝聚力及公司竞争力，促进企业长期可持续发展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118781164","title":"恒瑞医药公布2026年A股员工持股计划草案：拟受让不超过1,285.5万股回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1118781164","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118781164?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:13","pubTimestamp":1787148795,"startTime":"0","endTime":"0","summary":"2026年8月19日，恒瑞医药公告披露《江苏恒瑞医药股份有限公司2026年A股员工持股计划（草案）》。根据草案，公司拟向员工持股计划非交易过户不超过1,285.5万股已回购的A股股份，占公告日公司总股本的0.19%，受让价格为26.21元/股，资金来源为员工合法薪酬、自筹资金等，公司不提供任何财务资助。单个员工通过全部有效员工持股计划所持股份占公司总股本的比例不得超过1%，全部有效员工持股计划合计持股比例不超过10%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187204812","title":"恒瑞医药(01276)薪酬与考核委员会同意推进2026年A股员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1187204812","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187204812?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:13","pubTimestamp":1787148790,"startTime":"0","endTime":"0","summary":"财联社上海讯，2026年8月19日，江苏恒瑞医药股份有限公司 在上海证券交易所官网披露，公司董事会薪酬与考核委员会已对《江苏恒瑞医药股份有限公司2026年A股员工持股计划(草案)》及其摘要完成审阅，并形成核查意见。基于以上核查结论，薪酬与考核委员会同意实施此次员工持股计划，并同意将相关议案提交董事会审议。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197753739","title":"恒瑞医药（01276）披露2026年A股员工持股计划 最长存续60个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1197753739","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197753739?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:13","pubTimestamp":1787148786,"startTime":"0","endTime":"0","summary":"8月19日，恒瑞医药在香港联交所公告，其已于2026年8月18日至19日先后召开职工代表大会、董事会薪酬与考核委员会及第十届董事会第四次会议，审议通过《江苏恒瑞医药股份有限公司2026年A股员工持股计划（草案）》及相关议案，并发布由北京市中伦律师事务所出具的专项法律意见书。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113765318","title":"恒瑞医药（01276）公布2026年A股员工持股计划 最高受让1285.5万股回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1113765318","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113765318?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:13","pubTimestamp":1787148785,"startTime":"0","endTime":"0","summary":"2026年8月19日，恒瑞医药发布《2026年A股员工持股计划草案摘要公告》，拟面向不超过1,269名员工实施员工持股计划，核心要点如下：。计划受让公司回购专用证券账户中的A股股份不超过1,285.5万股，占公司总股本约0.19%。本次员工持股计划旨在建立公司、股东与员工的利益共享机制，增强员工凝聚力并提升公司竞争力。公告称，全部有效员工持股计划持股数量累计不超过公司总股本的10%，单一持有人对应股份不超过1%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132256246","title":"恒瑞医药（01276）公布2026年上半年业绩：净利润44.65亿元，同比微增0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132256246","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132256246?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:02","pubTimestamp":1787148128,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司8月19日在上海证券交易所及香港联合交易所披露2026年半年度报告摘要。期内公司主要财务表现如下：。截至2026年6月30日，公司总资产为707.73亿元，较上年末增长1.30%。上半年营业收入为154.56亿元，同比下降1.94%。利润总额49.52亿元，同比下降1.95%。归属于上市公司股东的净利润44.65亿元，同比增长0.34%。公司提醒投资者，以上数据摘自未经审计的半年度报告摘要，详细内容请查阅上海证券交易所及香港联合交易所网站披露的报告全文。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135452348","title":"恒瑞医药(01276)董事会通过多项激励及回购方案 将提交临时股东会审议","url":"https://stock-news.laohu8.com/highlight/detail?id=1135452348","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135452348?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:01","pubTimestamp":1787148098,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司8月19日公告，第十届董事会第四次会议以现场结合通讯方式召开，11名董事全部出席，会议审议并通过十项议案，核心内容如下：。恒瑞医药表示，上述需股东大会审议的议案将提交公司2026年第一次临时股东大会以特别或普通决议方式表决。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142831690","title":"恒瑞医药（01276）联席公司秘书刘笑含递交辞呈","url":"https://stock-news.laohu8.com/highlight/detail?id=1142831690","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142831690?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:01","pubTimestamp":1787148090,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司（01276）8月19日公告称，刘笑含已辞任公司联席公司秘书，自2026年8月19日起生效。刘笑含确认，其与董事会并无意见分歧，亦无其他事项需提请股东及香港联合交易所有限公司注意。\n刘笑含离任后，公司另一名联席公司秘书梁颖娴将继续留任，并担任公司唯一公司秘书。\n董事会对刘笑含任职期间的工作表示感谢。\n截至本公告日，恒瑞医药董事会成员包括：  \n(i) 执行董事孙飘扬、戴洪斌、冯佶、张连山、江宁军、孙杰平；  \n(ii) 非执行董事郭丛照；  \n(iii) 独立非执行董事楼丽广、曾庆生、孙金云、周纪恩。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660261584","title":"恒瑞医药(01276.HK)：刘笑含辞任联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2660261584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660261584?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:53","pubTimestamp":1787147621,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1023057109.AUD","LU2543165471.USD","01276","BK1191","LU0359202008.SGD","LU0359201612.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195245247","title":"恒瑞医药（01276）拟推出2026年H股股份计划　授权不超100万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195245247","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195245247?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:52","pubTimestamp":1787147540,"startTime":"0","endTime":"0","summary":"恒瑞医药8月19日公告称，公司董事会已于2026年8月19日审议通过并拟于2026年第一次临时股东大会上提交批准《2026年H股股份计划》。2026年H股股份计划将以受限制股份单位形式授予奖励，参与对象包括董事、高级管理层及其他核心人员。根据公告，计划的授权限额为不超过1,000,000股H股，占截至计划采纳日已发行H股总数的约0.4%，前提是假设自公告日起至采纳日期间公司未再配发、发行、回购或注销任何H股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426949","title":"恒瑞医药(01276)拟采纳2026 年H股股份计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426949","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660426949?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:50","pubTimestamp":1787147428,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年8月19日，董事会已议决建议采纳2026 年H股股份计划(2026年H股股份计划)。2026年H股股份计划将于即将举行的本公司2026年第一次临时股东会(股东会)上获批准后生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","BK0239","LU1655091616.SGD","LU1064130708.USD","LU1255011170.USD","600276","LU2543165471.USD","LU1781817850.SGD","LU2148510915.USD","LU2580892789.USD","LU0405327148.USD","LU2097828631.EUR","BK0188","LU0359201612.USD","LU1997244956.HKD","LU1328615791.USD","LU2580892862.HKD","BK0028","LU1820825898.SGD","BK0012","LU1969619763.USD","LU2097828557.USD","LU2328871848.SGD","BK0183","BK0196","LU2097828474.EUR","LU0359201885.HKD","LU1997245094.SGD","LU2488822045.USD","LU2289578879.USD","LU1580142542.USD","LU2097828805.USD","LU2097828714.EUR","LU1146622755.USD","01276","BK1191","LU2495084118.USD","LU1997245177.USD","LU1023057109.AUD","BK0060","LU1064131003.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176698593","title":"恒瑞医药（01276）发布2026年A股员工持股计划：规模不超1,285.5万股、受让价26.21元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=1176698593","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176698593?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:45","pubTimestamp":1787147157,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司于2026年8月19日公告，董事会已审议通过《2026年A股员工持股计划》，该计划尚待股东大会审议通过后方可生效。计划拟受让公司回购专用证券账户中的已回购A股股份，数量上限1,285.5万股，占公告日公司总股本的0.19%，受让价格为每股26.21元。单个持有人对应的标的股票数量不得超过公司总股本的1%，全部有效员工持股计划持股总数累计不得超过公司总股本的10%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660571426","title":"恒瑞医药(01276.HK)建议采纳2026年A股员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2660571426","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660571426?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:44","pubTimestamp":1787147058,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07233","83188","LU0359202008.SGD","03130","BK1147","83130","LU0359201885.HKD","02846","02827","LU0359201612.USD","01276","03188","BK1191","LU1023057109.AUD","LU2543165471.USD","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141413626","title":"恒瑞医药2026年中财报：营收154.56亿元，经调整净利润44.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141413626","media":"公告速递","labels":["SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141413626?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:43","pubTimestamp":1787147006,"startTime":"0","endTime":"0","summary":"恒瑞医药发布2026年中期财报显示，报告期内公司营收154.56亿元，同比下降1.9%。经调整净利润达44.65亿元，同比上升0.3%。经营活动产生的现金流净额为19.87亿元，同比减少约53.8%。报告期内，公司研发投入为46.05亿元，同比增长19.0%，其中费用化研发投入34.93亿元，同比增长8.2%，研发投入占营收比重为22.6%。公司销售及管理费用合计约57.41亿元，同比略降1.0%。财报指出，创新药业务收入增至88.09亿元，同比增长16.4%。对外许可收入14.22亿元，同比下滑28.6%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"恒瑞医药2026年中财报：营收154.56亿元，经调整净利润44.65亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0443},{"period":"3month","weight":-0.1194},{"period":"6month","weight":-0.2077},{"period":"1year","weight":-0.302},{"period":"ytd","weight":-0.2261}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}